Mirum Pharmaceuticals, Inc. MIRM revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Mirum Pharmaceuticals, Inc. reported revenue across 1 business segments; the largest, Reportable Segment, was $521M, 100.0% of the filed sum (+54.7% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$521M100.0%+54.7% yoy
Members sum to the consolidated $521M for this period.
- Reportable Segment-$22.1M100.0%-74.7% yoy
Members sum to the consolidated -$22.1M for this period.
- Product$521Mshare n/a+55.0% yoy
- Livmarli$360Mshare n/a+68.8% yoy
- Bile Acid Medicines$161Mshare n/a+31.0% yoy
- License And Other Revenue$0share n/a-100.0% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Product$160Mshare n/a+43.3% yoy
- Livmarli$114Mshare n/a+55.4% yoy
- Bile Acid Medicines$46.1Mshare n/a+20.1% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.